Αxicabtagene ciloleucel

Active ingredient description

Αxicabtagene ciloleucel, an engineered autologous T-cell immunotherapy product, binds to CD19 expressing cancer cells and normal B cells. Following anti-CD19 CAR T-cell engagement with CD19 expressing target cells, a sequence of events leads to apoptosis and necrosis of CD19-expressing target cells. Αxicabtagene ciloleucel is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL), after two or more lines of systemic therapy.

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

ATC code
Group title
Classification
Axicabtagene ciloleucel
L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01X Other antineoplastic agents → L01XX Other antineoplastic agents
Discover more medicines within L01XX70

Medicines

Αxicabtagene ciloleucel is the active ingredient of these drugs:

Drug
Countries

Austria Canada France Ireland Lithuania

Product monographs

Medicine agencies around the world have authorized marketing of this active ingredient according to these medication package inserts (MPIs):

Title
Type
Country
Summary of product characteristics (SPC)

Unique ingredient identifier (UNII)

U2I8T43Y7R - AXICABTAGENE CILOLEUCEL

SNOMED-CT

764088001 - Axicabtagene ciloleucel (substance)